PepGen Q3 2026 earnings

PEPG · 2026-11-10 08:00 BMO ET · 8-K on SEC · 10-Q on SEC

Clinical data from the 10 mg/kg cohort showed the highest splicing correction to date, while cash fell to $104.8M.

Headline numbers

not stated in the 8-K

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $20.4M (+9.4% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate 0.1% (prior-year 0%)
  • Non-GAAP bridge No reconciliation provided.

KPIs

MetricActualPrior quarterPrior yearChange
Cash, cash equivalents and marketable securities$104.8M$117.2M$148.5M-10.6% QoQ, -29.5% YoY
Weighted-average common stock outstanding69.3M69.3M34.4M0.0% QoQ, +101.5% YoY

Guidance

not stated in the 8-K

What drove it

  • Revenue story No revenue reported.
  • EPS story Net loss per share widened YoY due to higher operating expenses and share count, despite interest income.
  • One-off check not stated in the 8-K

The good

  • 10 mg/kg cohort demonstrated 46.5% mean splicing correction, the highest reported to date.
  • No treatment discontinuations, SAEs, or DLTs reported at 10 mg/kg.
  • DSMB recommended advancing to the 12.5 mg/kg cohort, which is fully enrolled.

The bad

  • Net loss increased YoY and QoQ.
  • R&D expenses increased YoY and QoQ.
  • Cash balance decreased QoQ to $104.8M.
  • Weighted-average shares outstanding increased YoY.

The ugly

  • none

Open questions

  • The release references a partial clinical hold on the FREEDOM2 study but does not disclose the specific nonclinical findings.
  • The release mentions an expansion cohort running in parallel to Cohort 3 but does not disclose the planned dose or size.
Full release

PepGen (PEPG) earnings release, November 10, 2026

PepGen Inc. (PEPG) · Form 8-K, Item 2.02 · Filed · SEC filing

PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights – Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures – – 12.5 mg/kg FREEDOM2-DM1 cohort fully enrolled, with participants having received up to three doses; results expected in 1H 2027 – – FREEDOM-OLE 10 mg/kg safety and 5 mg/kg clinical data expected in January 2027 – – Well-funded with $104.8M of cash as of September 30, 2026, sufficient to fund operations into 2028 – BOSTON— November 10, 2026--

PepGen Inc.

(Nasdaq: PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2026. PepGen also released today positive topline results from the 10 mg/kg multiple ascending dose cohort of the ongoing Phase 2 FREEDOM2-DM1 trial

(

NCT06667453) evaluating PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1), a rare, progressive, and multisystemic genetic disease.

“The positive 10 mg/kg cohort results we announced today were made possible by our team’s focused execution,” said James McArthur, Ph.D., President and Chief Executive Officer of PepGen. “We are very confident in PGN-EDODM1’s potential to deliver meaningful benefit to the DM1 community, and our company ended the quarter in a strong position to advance the program to the third and highest dose cohort, which is fully enrolled.”

Recent Program Updates

PGN-EDODM1: Myotonic Dystrophy Type 1 (DM1)

• FREEDOM2-DM1 Phase 2 Multiple Ascending Dose (MAD) 10 mg/kg Results: o

Topline data from the 10 mg/kg dose cohort demonstrated a mean splicing correction of 46.5%, the highest reported to date in a multiple dose study. Five of six participants demonstrated greater than 20% splicing improvement, and four participants had greater than 50% splicing improvement at Week 13. o

The data also showed notable improvements across multiple functional measures including video Hand Opening Time (vHOT), hand grip strength, 10-Meter Walk/Run Test (10MWRT), and Timed Up and Go (TUG). o

PGN-EDODM1 continued to be generally well tolerated at 10 mg/kg in the FREEDOM2 study with no treatment discontinuations, no serious or severe adverse events (SAE), and no dose-limiting toxicities (DLT) reported. o

Read the full release here.

• FREEDOM2-DM1 and FREEDOM-OLE Next Steps: o

Based on the review of available safety data from the 10 mg/kg MAD cohort and FREEDOM-OLE (OLE), an independent Data and Safety Monitoring Board (DSMB), recommended advancing the FREEDOM2 trial into the third and highest dose cohort (12.5 mg/kg). The 12.5 mg/kg cohort of FREEDOM2 is fully enrolled with all participants having received up to three doses and results are expected in the first half of 2027. o

The DSMB also approved dose escalation in the OLE from 5 mg/kg to 10 mg/kg. To date, >35 doses at 10 mg/kg and 100 doses at 5 mg/kg have been delivered and 19 participants are now enrolled in the OLE. Furthermore, there have been no SAEs, no DLTs, with one discontinuation occurring due to hypersensitivity reaction. Interim 10 mg/kg OLE safety and 5 mg/kg OLE clinical data are expected in January 2027. o

Building upon the positive results seen at 10 mg/kg, PepGen plans to initiate an expansion cohort, running in parallel to Cohort 3, to generate longer term (up to 9 months) data.

• PGN-EDODM1 Regulatory Updates: o

Data from the FREEDOM2 and FREEDOM-OLE studies (

NCT07220603) are expected to support an end-of-Phase 2 (EOP2) meeting in the second half of 2027 pending removal of the partial clinical hold. o

In March 2026, PepGen announced that the U.S. Food and Drug Administration (FDA) issued a partial clinical hold on the FREEDOM2 study citing nonclinical findings in mice. We are conducting nonclinical mouse studies and remain actively engaged with the FDA about conducting additional nonclinical mouse studies designed to generate data to respond to the FDA’s questions. o

In October 2026, under the currently open U.S. FDA IND, the FDA selected PGN-EDODM1 for its CMC Development and Readiness Pilot (CDRP) program. This program allows for enhanced regulatory engagement with the FDA to de-risk CMC development through structured, CDRP-enabled interactions. In addition, the program is designed to accelerate alignment on critical manufacturing development strategies ahead of Phase 3 and NDA submission.

Corporate Updates

• In September 2026, PepGen presented PGN-EDODM1 data at the 27th Annual Neuromuscular Study Group Scientific Meeting (NMSG) and the 31st Annual Congress of the World Muscle Society (WMS). The data were featured in oral and poster presentations at both NMSG and WMS. Paul Streck, M.D., MBA, PepGen's Executive Vice President, Head of Research and Development, presented FREEDOM and FREEDOM2 clinical data.

Financial Results for the Three Months Ended September 30, 2026

• Cash, Cash Equivalents and Marketable Securities were $104.8 million as of September 30, 2026. Based on currently planned operations, PepGen believes that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operations into 2028.

• Research and Development Expenses were $14.5 million for the three months ended September 30, 2026, compared to $13.4 million for the same period in 2025.

• General and Administrative Expenses were $5.9 million for the three months ended September 30, 2026, compared to $5.2 million for the same period in 2025.

• Net Loss was $19.4 million, or $(0.28) basic and diluted net loss per share, for the three months ended September 30, 2026, compared to $18.0 million, or $(0.52) basic and diluted net loss per share, for the same period in 2025. PepGen had approximately 69.3... (truncated)tember 30, 2026.

About Myotonic Dystrophy Type 1 (DM1)

Myotonic dystrophy type 1 (DM1) is a rare, progressive genetic disease that affects muscles and multiple systems throughout the body. DM1 is caused by an abnormal expansion of cytosine-thymine-guanine (CTG) repeats in the dystrophia myotonica protein kinase (

DMPK) gene, resulting in pathogenic RNA that interferes with normal RNA splicing and drives the disease. Symptoms can begin in childhood or adulthood and vary widely in type, severity, and progression. DM1 has a world-wide distribution and is estimated to affect more than 110,000 people across the United States and the European Union, and average life expectancy for people with non-congenital DM1 is approximately 50 to 60 years. No approved therapies currently address the underlying cause of DM1.

About PGN-EDODM1

PGN-EDODM1 is an investigational Enhanced Delivery Oligonucleotide (EDO) designed to address the underlying molecular mechanism of DM1. Using PepGen’s proprietary EDO technology designed to enhance cellular uptake and nuclear delivery of a therapeutic oligonucleotide, PGN-EDODM1 selectively binds to expanded CUG repeats in pathogenic dystrophia myotonica protein kinase (

DMPK) RNA. This binding releases MBNL1, a key regulator of RNA splicing, to restore correct splicing. Unlike approaches that degrade

DMPK

RNA, PGN-EDODM1 is designed to disrupt pathogenic

DMPK hairpin structures while preserving normal

DMPK function. The U.S. Food and Drug Administration has granted PGN-EDODM1 Orphan Drug and Fast Track designations, and the European Medicines Agency has granted it Orphan Designation.

About FREEDOM2-DM1

FREEDOM2-DM1 (

NCT06667453) is a multinational, randomized, double-blind, placebo-controlled Phase 2 multiple ascending dose study evaluating PGN-EDODM1 in people living with

DM1. The study enrolled three cohorts of eight participants each, randomized 3:1 to receive PGN-EDODM1 or placebo at doses of 5, 10, or 12.5 mg/kg. Participants receive four intravenous doses every four weeks over 12 weeks. Key endpoints include safety and tolerability, pharmacokinetics, correction of RNA mis-splicing in muscle tissue, and functional measures of myotonia, strength, and mobility. FREEDOM2 is being conducted in Canada, the United Kingdom, New Zealand, Australia, and South Korea and is subject to a partial clinical hold in the United States. Eligible participants may continue treatment in the FREEDOM-OLE study.

About PepGen

PepGen Inc. is a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases. Founded on more than a decade of research and development, PepGen’s Enhanced Delivery Oligonucleotide (EDO) technology leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using this EDO technology, PepGen is advancing PGN-EDODM1, a clinical candidate for the treatment of myotonic dystrophy type 1.

For more information, please visit

PepGen.com. Follow PepGen on

LinkedIn and

X.

Financial statements

Income Statement

Three Months Ended September 30, — (unaudited, in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
Operating expenses:
Research and development14,47613,423
General and administrative5,9075,231
Total operating expenses20,38318,654
Operating loss-20,383-18,654
Other income (expense)
Interest income1,005634
Other (expense) income, net-6
Total other income, net1,005628
Net loss before income tax-19,378-18,026
Income tax expense-13
Net loss-19,391-18,026
Net loss per share, basic and diluted-0.28-0.52
Weighted-average common stock outstanding, basic and diluted69,260,35334,362,876

Balance Sheet

September 30, 2026 — (unaudited, in thousands)

September 30, 2026December 31, 2025
Assets
Cash, cash equivalents and marketable securities104,805148,456
Other assets22,97225,451
Total assets127,777173,907
Liabilities and stockholders’ equity
Liabilities24,71126,463
Stockholders’ equity103,066147,444
Total liabilities and stockholders’ equity127,777173,907

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (UNAUDITED) (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-54,966-71,315
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation8121,061
Stock-based compensation expense9,1338,172
Amortization and interest accretion related to operating lease2,8112,811
Amortization of premiums and accretion of discounts on marketable securities, net-2,593-1,441
Impairment of long-lived assets701
Changes in operating assets and liabilities:
Prepaids and other current and non-current assets1141,028
Accounts payable1,104-971
Accrued expenses and other non-current liabilities-1,440-3,523
Operating lease liabilities, current and non-current-2,382-2,313
Net cash used in operating activities-47,407-65,790
Cash flows from investing activities:
Purchases of property and equipment-30-265
Purchases of marketable securities-100,487-6,726
Maturities of marketable securities108,00058,000
Net cash provided by investing activities7,48351,009
Cash flows from financing activities:
Issuance of common stock from At-the-Market Sales Agreement, net of underwriters' fees1,511
Issuance of common stock in public offering, net of underwriters' fees108,100
Payment of offering costs-265-75
Proceeds from employee equity plans121125
Net cash provided by financing activities1,367108,150
Effect of exchange rate changes on cash-15
Net (decrease) increase in cash, cash equivalents and restricted cash-38,55793,354
Cash, cash equivalents and restricted cash at beginning of period62,06250,969
Cash, cash equivalents and restricted cash at end of period23,505144,323
Components of cash, cash equivalents and restricted cash
Cash and cash equivalents21,957142,775

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the therapeutic potential and safety profile of PGN-EDODM1, statements regarding PGN-EDODM1’s potential to deliver meaningful benefit to the DM1 community, expectations regarding the timing of data for the 12.5 mg/kg cohort of the FREEDOM2-DM1 trial, the

FREEDOM-OLE 10 mg/kg safety and 5 mg/kg clinical results, our plans to initiate an expansion cohort running in parallel to cohort 3, timing regarding the end-of-Phase 2 (EOP2) meeting for FREEDOM2 and FREEDOM-OLE studies, the potential for the CDRP program to accelerate alignment on critical manufacturing development strategies ahead of Phase 3 and NDA submission, forecasts relating to PepGen’s cash runway, and ongoing and planned regulatory interactions, including the potential timing and successful resolution of questions from the FDA relating to the partial clinical hold.

Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: delays or failure to successfully initiate or complete our ongoing... (truncated)ce to commence planned clinical studies of our product candidates including the lifting of the partial clinical hold on PGN-EDODM1, or other regulatory feedback requiring modifications to our development programs, including in each case with respect to our

PGN-EDODM1 program; changes in regulatory framework that are out of our control; unexpected increases in the expenses associated with our development activities or other events that adversely impact our financial resources and cash runway; and our dependence on third parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning PepGen’s programs and operations are described in our most recent reports filed with the SEC. PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

This release discusses PGN-EDODM1, an investigational therapy that has not been approved for use in any country, and is not intended to convey conclusions about its efficacy or safety. There is no guarantee that PGN-EDODM1 or any other investigational therapy will successfully complete clinical development or gain approval from regulatory authorities.

Condensed Consolidated Statements of Operations

(unaudited, in thousands)

Condensed Consolidated Balance Sheets

(unaudited, in thousands)

Investor Contact

Laurence Watts

New Street Investor Relations laurence@newstreetir.com

Media Contact

Amir Khan

Chamberlain Healthcare PR

Amir.Khan@syneoshealth.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · PepGen earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.